These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 23106476

  • 1. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
    Kwakernaak AJ, Lambert G, Muller Kobold AC, Dullaart RP.
    Thyroid; 2013 Feb; 23(2):166-72. PubMed ID: 23106476
    [Abstract] [Full Text] [Related]

  • 2. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ, Lambert G, Dahlbäck B, Nielsen LB, Dullaart RP.
    Atherosclerosis; 2011 Feb; 214(2):492-4. PubMed ID: 21122852
    [Abstract] [Full Text] [Related]

  • 3. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schaper NC, Schalkwijk CG, Konrad RJ, Stehouwer CD.
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [Abstract] [Full Text] [Related]

  • 4. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 5. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
    [Abstract] [Full Text] [Related]

  • 6. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 7. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
    Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB.
    Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1585-95. PubMed ID: 22580899
    [Abstract] [Full Text] [Related]

  • 8. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC, Wong AT, Pang J, Barrett PH, Watts GF.
    Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
    [Abstract] [Full Text] [Related]

  • 9. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chrétien M, Faraj M.
    J Clin Lipidol; 2015 Mar; 9(5):664-75. PubMed ID: 26350813
    [Abstract] [Full Text] [Related]

  • 10. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
    Ozkan C, Akturk M, Altinova AE, Cerit ET, Gulbahar O, Yalcin MM, Cakir N, Balos Toruner F.
    Endocr J; 2015 Jan; 62(12):1091-9. PubMed ID: 26490048
    [Abstract] [Full Text] [Related]

  • 12. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [Abstract] [Full Text] [Related]

  • 13. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [Abstract] [Full Text] [Related]

  • 14. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 15. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y, Ma Y, Ye Z, Fu Z, Yang P, Gao B, Guo W, Hu D, Ye J, Ma S, Zhang F, Zhou L, Xu X, Li Z, Yang T, Zhou H.
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [Abstract] [Full Text] [Related]

  • 16. Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels.
    Aung LH, Yin RX, Wu DF, Cao XL, Hu XJ, Miao L.
    Int J Med Sci; 2013 Nov; 10(2):124-32. PubMed ID: 23329883
    [Abstract] [Full Text] [Related]

  • 17. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
    Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP.
    Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
    [Abstract] [Full Text] [Related]

  • 18. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B.
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [Abstract] [Full Text] [Related]

  • 19. Associations Between Thyroid Hormones Within the Euthyroid Range and Indices of Obesity in Obese Chinese Women of Reproductive Age.
    Du FM, Kuang HY, Duan BH, Liu DN, Yu XY.
    Metab Syndr Relat Disord; 2019 Oct; 17(8):416-422. PubMed ID: 31355704
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J, Bogsrud MP, Tveten K, Strøm TB, Holven K, Berge KE, Leren TP.
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.